FibroGen to Participate at Bank of America 2022 Biotech SMID Cap Virtual ConferenceGlobeNewsWire • 11/28/22
FibroGen Announces $50 Million Royalty Monetization Financing with NovaQuest Capital ManagementGlobeNewsWire • 11/07/22
Earnings Preview: FibroGen (FGEN) Q3 Earnings Expected to DeclineZacks Investment Research • 10/31/22
FibroGen Announces Completion of Patient Enrollment in MATTERHORN, a Phase 3 Clinical Study of Roxadustat for the Treatment of Anemia in Patients with Lower Risk Transfusion-Dependent Myelodysplastic Syndromes (MDS)GlobeNewsWire • 08/26/22
FIBROGEN INVESTIGATION CONTINUED by Former Louisiana Attorney General: Kahn Swick & Foti, LLC Provides Update of its Investigation of the Officers and Directors of FibroGen, Inc. - FGENBusiness Wire • 08/20/22
FibroGen, Inc. (FGEN) CEO Enrique Conterno on Q2 2022 Results - Earnings Call TranscriptSeeking Alpha • 08/09/22
FibroGen Announces Completion of Patient Enrollment in LELANTOS-2, a Phase 3 Clinical Study of Pamrevlumab in Duchenne Muscular DystrophyGlobeNewsWire • 06/08/22
FIBROGEN INVESTIGATION CONTINUED by Former Louisiana Attorney General: Kahn Swick & Foti, LLC Continues to Investigate the Officers and Directors of FibroGen, Inc. - FGENBusiness Wire • 05/28/22
FibroGen, Inc.'s (FGEN) CEO Enrique Conterno on Q1 2022 Results - Earnings Call TranscriptSeeking Alpha • 05/10/22